TECHNIQUE: Risks and potential complications were explained and a informed was written consent. Patient was placed on prone position on fluoroscopy table. Back prepped and draped in usual sterile fashion. 1% Lidocaine was used for Local anesthesia.[ L2-3 or L3-4] interspace was localized. Under fluoro guidance, a G spinal needle was advanced along the right paramidline interlaminar space into the thecal space with a single pass. Needle placement was confirmed with passive flow of clear CSF. Opening pressure was measured to be cm of water. cc CSF was collected and sent to lab for analysis. [12cc] of  was introduced into thecal sac. Subsequently, CT scan was performed from [T12-S1]. No immediate post-procedure complications.
Other study results included a 6 percent increase in pain severity scores for dogs in the control group, while the dogs in the SP-sap group had no change in pain severity score. In addition, the dogs in the control group had an 8 percent increase in how pain interferes with their typical activities, while the SP-sap dogs had a 5 percent improvement in this pain impact score. Finally, one dog in the control group responded with improved lameness, while 6 dogs in the SP-sap group became less lame. While these secondary study results were not statistically significant because they were only assessed two weeks after injection, they are promising.
In the FDA clinical study, the coflex ® device was compared to pedicle screw spinal fusion surgery (surgical decompression with spinal fusion surgery for spinal stenosis). The objective of this study was to see if the coflex ® device was safe and if it would work in patients who had moderate to severe spinal stenosis. In the FDA study, it is proven that the coflex ® device is a reasonable alternative to pedicle screw fusion, and results showed that coflex ® patients outperformed fusion patients in all clinical measurements!*